You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

Ertapenem sodium - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for ertapenem sodium
US Patents:0
Tradenames:2
Applicants:6
NDAs:6
Drug Master File Entries: 8
Finished Product Suppliers / Packagers: 14
Raw Ingredient (Bulk) Api Vendors: 88
Clinical Trials: 12
Patent Applications: 647
What excipients (inactive ingredients) are in ertapenem sodium?ertapenem sodium excipients list
DailyMed Link:ertapenem sodium at DailyMed
Recent Clinical Trials for ertapenem sodium

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2
Merck Sharp & Dohme Corp.Phase 4
Albany College of Pharmacy and Health SciencesPhase 4

See all ertapenem sodium clinical trials

Pharmacology for ertapenem sodium
Paragraph IV (Patent) Challenges for ERTAPENEM SODIUM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INVANZ Injection ertapenem sodium 1 g/vial 021337 1 2012-12-21

US Patents and Regulatory Information for ertapenem sodium

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acs Dobfar Spa ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 208790-001 Apr 16, 2018 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 209145-001 May 2, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Savior Lifetec Corp ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 207647-001 Mar 19, 2019 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Gland Pharma Ltd ERTAPENEM SODIUM ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 212040-001 Mar 26, 2021 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ertapenem sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, INTRAVENOUS 021337-001 Nov 21, 2001 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.